Peter Fredette brings 25 years of expertise in the drug development industry, encompassing pre-clinical toxicology and all phases of clinical research. His extensive career spans roles in CRO, Biotech, and Site sectors, as well as multiple volunteer and advisory board appointments. Specializing in oncology research, Peter has also contributed to drug development across multiple therapeutic areas.  Renowned for his industry knowledge and collaborative approach, Peter continuously seeks opportunities to drive improvements and foster enduring relationships in the research field, all focused on the quality and accessibility of clinical trials worldwide.